Keywords: USA, Regulatory process, Benefit risk, FDA
Appropriate assessment of both benefits and risks critical in US regulatory process, says Lilly CEO
Article | 02 November 2011
To sustain medical innovation, the US Food and Drug Administration must accelerate the adoption of a Benefit-Risk framework to inform ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
